Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | PDE6D | O43924 | 6/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30789263 | 0.95 | ALDH1A1 (0.59) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL30789261 | 0.94 | ESR1 (0.52) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL30789250 | 0.88 | ALDH1A1 (0.61) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL30789282 | 0.87 | ALDH1A1 (0.60) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL5579681 | 0.86 | ALDH1A1 (0.62) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL30789276 | 0.85 | TP53 (0.71) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL30789243 | 0.85 | ALDH1A1 (0.58) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL30789245 | 0.85 | ALDH1A1 (0.58) | ALDH1A1HTTTP53SMN1; SMN2MAPT | |
| SCHEMBL5579673 | 0.85 | PTGES (0.64) | MAPTLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL30789246 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HTTTP53SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| EP-1341768-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046168-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | ALDH1A1 307/4885HTT 2019/4885TP53 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.